Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

1.2K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.2K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

104
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
104
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

149
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
149
Pulse rhythm01:30

Pulse rhythm

910
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
910
Dysrhythmias VII: Nursing Management of Dysrhythmias01:25

Dysrhythmias VII: Nursing Management of Dysrhythmias

102
Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...
102
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

29
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
29

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Impact of a balloon-in-basket pulsed field ablation catheter on oesophageal temperature changes during pulmonary vein isolation.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Interactions of blood biomolecules with early rhythm control in atrial fibrillation patients: Exploratory analysis of the EAST-AFNET 4 Biomolecule Study.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Edoxaban for Stroke Prevention in Atrial Fibrillation in Spain and Portugal: 4-Year Follow-Up of the Observational ETNA-AF-Europe Study.

Journal of clinical medicine·2026
Same author

Analgosedation for catheter ablation in deep sedation: comparison between cryoballoon and pulsed field ablation.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

AF-B-STEP: a global collaboration to reduce the burden of atrial fibrillation and advance its quantification and treatment.

European heart journal·2026
Same author

A titin truncating variant linked to atrial fibrillation increases atrial profibrotic signalling and cholinergic sensitivity.

Cardiovascular research·2026

関連する実験動画

Updated: Sep 1, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

アトリアルフィブリレーションと高併発症の患者の早期リズム制御

Andreas Rillig1,2, Katrin Borof1, Günter Breithardt3,4

  • 1Department of Cardiology, University Heart and Vascular Center (A.R., K.B., A.M., P.K.), University Medical Center Hamburg-Eppendorf, Germany.

Circulation
|August 15, 2022
PubMed
まとめ

早期リズムコントロール (ERC) は,心房細動と脳卒中リスクが高い患者 (CHA2DS2- VAScスコア ≥4) に有益です. しかし,併発症が少ない患者では,ERCが有害事象を増加させる可能性があります (CHA2DS2- VAScスコア< 4).

キーワード:
抗不律剤心房細動心房細動の消去併発症死亡ストローク

さらに関連する動画

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

1.8K

関連する実験動画

Last Updated: Sep 1, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

1.8K

科学分野:

  • 心臓病科
  • 臨床試験
  • アトリアルフィブリレーションの管理

背景:

  • EAST- AFNET4試験では,脳卒中の危険因子のある,最近発症した心房細動 (AF) の場合,早期リズムコントロール (ERC) が心血管疾患を減少させることが示されました.
  • 複数の併発性心血管疾患を有する患者のERCの有効性と安全性は不明である.

研究 の 目的:

  • 高い (CHA2DS2- VAScスコア ≥4) と低い併発症の患者におけるERCと通常の治療 (UC) の有効性と安全性を比較する.
  • 併発症の負担によって層分けされたERCの結果を分析する.

主な方法:

  • EAST-AFNET4試験の予め指定されたサブ分析
  • 患者は,より高い (CHA2DS2- VAScスコア ≥4) およびより低い (CHA2DS2- VAScスコア < 4) 併発症群に分類された.
  • ERC と UC の有効性 (複合的原始有効性結果) と安全性 (原始安全性結果) は,層内で比較されました.

主要な成果:

  • CHA2DS2- VAScスコア ≥4の併発性重症患者では,ERCは,主効性評価値 (HR,0. 64; P < 0. 001) を著しく低下させ,主安全性評価値 (HR,0. 84; P=0. 175) を増加させなかった.
  • 併発性重症 (CHA2DS2- VAScスコア< 4) の患者では,ERCは主効性アウトカム (HR,0. 93; P=0. 56) を低下させず,主安全性アウトカム (HR,1. 39; P=0. 019) を増加させた.
  • 性別別別分析では,女性の性別を無視した安全性に関する有意な相互作用が示された (P=0. 044).

結論:

  • 最近診断された心房細動とCHA2DS2- VAScスコアが4以上である患者に,心血管不良を減らすために早期のリズムコントロール (ERC) が推奨されます.
  • 併発症が少ない患者 (CHA2DS2- VAScスコア < 4) は,通常の治療と比較して,ERCで好ましい結果と安全性のリスクが増加することがあります.